Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 JTE-061 cream in pediatric atopic dermatitis
jRCT2031230139Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing JTE-061 cream 0.5% with Vehicle cream / JTE-061 cream 0.5% extension (2 arms). Primary endpoint: EASI-75 response at Week 8. Started Aug 2023; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230139.